Top 6 Companies in the Infertility Drugs Market in 2025

The infertility drugs market was valued at USD 3.70 Billion in 2024. The market is expected to grow at a CAGR of 5.9% during the forecast period of 2025-2034, with the values likely to reach USD 6.56 Billion by 2034. The market is driven by the increasing prevalence of infertility across the 8 major markets.

Infertility drugs are used to treat infertility caused by various factors in both men and women. They can stimulate hormone production, regulate ovulation, or increase the count and quality of sperm. The most prescribed drugs include clomiphene citrate, gonadotropins, and aromatase inhibitors, typically for women with ovulation-related disorders. For men, these drugs help increase sperm count or regulate hormone levels. Often used in assisted reproductive technologies such as in vitro fertilization (IVF) and intrauterine insemination (IUI), fertility medications offer hope to those struggling with infertility when other methods of conception have failed.

The growth of the infertility drug market can be attributed to several factors, including increased awareness, lifestyle changes, and advancements in reproductive health treatments. As infertility rates rise globally, the demand for pharmaceutical solutions has surged. The market is further fueled by the increasing number of people seeking fertility treatments and better success rates due to advancements in drug development. Strong market growth has been seen mainly due to innovations in hormone-based therapies and reproductive technologies. Other factors that are contributing to the market growth are the rising government support and investment in healthcare.

In October 2024, Lupin launched Ganirelix Acetate Injection, an infertility treatment injection in the United States, marking a significant development in infertility drug treatments. This injectable therapy addresses hormonal imbalances in assisted reproductive procedures, enhancing patient outcomes. Lupin's entry into this market reflects the increasing demand for advanced fertility treatments, positioning the company as a key driver of market growth in this sector.

Let’s explore the profile of top companies leading the infertility drugs market in 2025.

1. Merck KGaA

Merck has remained a prominent player in the infertility drugs market with its innovative fertility treatments. It manufactures medicines intended to cure or treat infertility and supports Assisted Reproduction Technologies. The company also emphasizes research and development and contributes towards enhancing fertility care, particularly through its hormone-based therapies, IVF treatments, and other advanced fertility solutions, in response to the growing demand for successful reproductive healthcare.

2. Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals has been a leading player in the infertility drugs market, specializing in reproductive medicine and maternal health. The company has focused on advancing treatments for infertility, including medications for in vitro fertilization (IVF) and hormone therapies. With a commitment to improving patients' lives, the company has developed innovations designed to ensure the efficacy of fertility therapies and promote optimal maternal health with wide-ranging care, ensuring better health outcomes.

3. Novartis AG

Novartis, a global healthcare leader, has contributed to the market for infertility drugs. Its medications are used by women with ovulation-related infertility. The drug Femara is particularly effective in inducing ovulation, especially when used in conjunction with assisted reproductive technologies like in-vitro fertilization. Through the improvement of reproductive health, the company plays an important role in improving fertility treatment options and providing a solution for overcoming infertility challenges.

4. Theramex HQ UK Limited

Theramex HQ Limited is headquartered in the UK and is actively involved in the infertility drugs market with a portfolio of fertility treatments. The company has an emphasis on offering medicine supporting assisted reproduction and providing products for ovulation induction, hormone regulation, or in vitro fertilization. It also ensures improvements in reproductive health and offers remedies to address obstacles to improving fertility.

5. Teva Pharmaceuticals Industries Ltd.

Teva Pharmaceutical Industries Ltd. is a major player in the women's health and infertility drug market. The company has focused on providing a variety of pharmaceutical solutions for reproductive health, including treatments related to infertility. The company seeks to provide affordable and accessible medications that address fertility issues, contributing to the advancements in reproductive healthcare.

6. Livzon Pharmaceutical Group Inc.

Livzon Pharmaceutical significantly contributes to the market growth of infertility drugs. The company majorly focuses on developing and manufacturing pharmaceutical products that are used to improve reproductive health. Their portfolio includes drugs that are designed to address a variety of fertility challenges, supporting assisted reproductive technologies and hormone therapies. Through continuous innovation and research, the company has supported the advancement of infertility treatments, aiming to provide effective solutions for individuals and couples struggling with fertility issues.